Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7: early-phase trial registry
1 of 6 indexed Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7: 6 US clinical trials tracked, 1 recruiting.
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition stage-iii-oropharyngeal-squamous-cell-carcinoma-ajcc-v7
OPEN 1 | RECR 17% | LATE 1 | EARLY 5 | RANK #2866 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 is recruiting below its size-band peers.
1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 research.
M.D. Anderson Cancer Center accounts for 3 of 6 trials (50%). 2 distinct sponsors appear on at least one study for this condition label.
-
Most Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 trials plan to enrol fewer than 100 people.
Median target enrolment is 43 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.
-
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
NCT01810913
Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer
M.D. Anderson Cancer Center
NCT01893307
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
National Cancer Institute (NCI)
NCT02567422
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
M.D. Anderson Cancer Center
NCT03799445
Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer
M.D. Anderson Cancer Center
NCT03144778
Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
NCT02775812
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 page
6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 condition card totals 6 registered trials; most-linked intervention Intensity-Modulated Radiation Therapy; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.